AzTrials
AzTrials

Caesarean SectionNCT06979687

Knotless Barbed Suture Closure of the Uterus at Caesarean Section

An observational study of Caesarean Section and Caesarean Section; Infection, run by South Tees Hospitals NHS Foundation Trust at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Caesarean section (CS) is an increasingly common mode of delivery. The way in which this operation is carried out is important as it affects millions of women each. In recent years use of a 'self-retaining' suture or thread for closure of the uterine closure has become a recognised approach with a proven safety… Read more about this study

Who is it for?
Any age, women only
What is being tested?
knotless barbed suture closure of the hysterotomy at caesarean section and Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)
Type of treatment
Surgery or procedure
How many people
957 participants
Where
1 siteUnited Kingdom
Study dates
1 Nov 2022to 11 Feb 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Women having a caesarean section at James Cook University Hospital within the study period

Who may be able to join

  • Women undergoing a caesarean section at the study hospital within the data collection period for that cohort - either with or without KBS depending on the cohort.

Who cannot join

  • Not falling within the search criteria for a comparator group

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • James Cook University Hospital

    Middlesbrough, TS43BW

Other trials in United Kingdom

About this study

Caesarean section (CS) is an increasingly common mode of delivery. The way in which this operation is carried out is important as it affects millions of women each. In recent years use of a 'self-retaining' suture or thread for closure of the uterine closure has become a recognised approach with a proven safety record. These sutures are known as knotless barbed sutures (KBS) as the unidirectional barbs on the surface of the suture hold the suture in the tissue without the need for knots. These sutures can be used instead of the usual 'smooth' suture which requires knots at the angles. There are high-level level data that CS are quicker and on average need fewer additional stitches to control blood loss when KBS are used. There is additional evidence of a potential reduction in problems with healing of the uterus with KBS, it is thought that this might lead to a lower risk of problems in repeat CS as the chance of the placenta implanting into the scar might be lower. At present this evidence is based on ultrasound surveillance of scar appearance which is an indirect measure. The real risk difference will need to be explored with the examination of real world outcomes over the coming years.

There is currently no published data on KBS for uterine closure at caesarean from the UK. This cohort, although retrospective, is adequately controlled, shows excellent outcomes and signals a potential marked reduction in infectious morbidity. This potentially means a better patient experience as well as a large cost saving because of reduced re-admission rates. These data were collected as part of a service improvement project but the generalisable nature of our findings mean the finding are research and should be published.

Read the detailed description

Caesarean section (CS) is one of the most commonly performed operations worldwide and the prevalence is increasing1. There are perioperative complications including neonatal morbidity and, on the maternal side, haemorrhage, infection and organ injury2. Furthermore, there are implications for future pregnancies, the risks of which rise with each successive caesarean3. Closure of the lower segment hysterotomy at CS is most commonly affected using a 2-layer approach employing braided absorbable sutures such as Vicryl (polyglactin 910)4. Closure is with a continuous suturing technique and the tension of the closure is maintained manually until the suture is secured with knots at the angles. Knotless barbed suture (KBS) closure of the caesarean hysterotomy remains a novel technique that is not yet widely employed. These sutures, first invented in 1964, were approved by the FDA in 2004 and were first used in a clinical trial in 20075. Barbed sutures anchor themselves within the tissue, as barbs on the suture resist backward movement through the tissue. They offer even tension over the length of the hysterotomy and are cut flush with the uterus without the need for anchoring knots.

A systematic review and meta-analysis of randomised control trials (n460) on KBS compared with 'smooth' sutures at elective CS found that operative times were lower and the need for additional haemostatic sutures was lower6. There was a trend towards lower blood loss and no difference in operative morbidity. Some trials, some of which are ongoing, have examined whether there is a difference in lower segment residual myometrial thickness (RMT) after KBS and whether there is a difference in the incidence of scar niche7. These outcomes, respectively, are offered as potential proxy measures for uterine rupture risk and praevia or PAS risk. The results of these trials, as per their proxy outcomes, have been encouraging. This trial offers the first data on KBS at CS in UK practise.

Methods:

This single-centre retrospective cohort study in a tertiary care hospital in Northern England including caesarean deliveries from November 2022 to October 2024 - a 24 month period. The cohorts are women who had a Medtronic's V-loc 180 absorbable device (KBS) and women who had 2 layer vicryl (polyglactin 910) uterine closure i.e. smooth suture (SS).

Data was collected prospectively using a Microsoft Excel™ spreadsheet by the lead clinician (HS) as part of a quality improvement project and data was cross-referenced with patient records using Clevermed badgernotes ™ maternity system data records. Baseline characteristics reported are: patient age at delivery, parity, number of previous caesarean sections, BMI at booking, additional intraoperative interventions, birth-weight, indication for, and category of, caesarean, mode of anaesthesia, grade of operator and whether a consultant was present if not the primary surgeon (Table 1). The pre-specified outcome was blood loss. The pre-specified secondary outcomes were operating time, infection rates, readmission, unplanned outpatient attendance, and other complications.

Women were grouped for comparison as follows: group 1, n290 elective CS undertaken using KBS (November 2022-December 2024); group 2 - n215 Elective caesareans undertaken on a number of consultant lists using SS (May-August 2024). Group 3 - n107 Emergency caesarean deliveries using KBS (January 2023-December 2024); Group 4 - n345 emergency caesarean deliveries using SS (May-August 2024). Group 5 - n397 comprises group 1 and group 3. Group 6 - n560 comprises group 2 and group 4. The plan for data analysis was pre-specified and published prior to analysis being undertaken.

The investigators report baseline characteristics and outcomes as means (SDs), or numbers and percentages. Difference in outcome by cohort is reported as relative risk with 95% CI. Multivariate analysis was used to assess correlation for inclusion of variables in binary logistic regression for adjustment of risk. Variables felt relevant were included regardless of significance of correlation, as pre-specified - for the primary outcome, across all three comparisons, the following variables were pre-selected for inclusion in adjustment of risk: BMI, birthweight, mode of anaesthesia. For the secondary outcomes pre-specified variables for adjustment of risk across all three comparisons were as follows: for operating time; BMI, additional operative interventions, number of previous caesareans, for infection rates; BMI, category of caesarean and indication, for readmission; BMI and category of caesarean, for unplanned outpatient attendances as for readmission. There was no planed adjustment for the safety outcome of other complications. Unpaired t-tests, Chi square or Fisher's exact test were used to test significance for categorical and continuous outcomes. Analysis was carried out using IBM SPSS version 24. Alpha was taken as 0.05 for the primary outcome and 0.01 for the secondary outcomes.

Being tested
knotless barbed suture closure of the hysterotomy at caesarean section, Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)
Keywords
Knotless barbed suture, caesarean section, caesarean delivery, caesarean birth
Medical subject headings
Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • knotless barbed suture closure of the hysterotomy at caesarean sectionProcedure or surgery

    Use of Medtronic V-loc 180 suture (VL) for a 2 layer closure of the caesarean hysterotomy rather than the standard 2 layer closure using the 910 polyglactin suture (SS).

  • Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)Procedure or surgery

    Standard 2 layer closure using the 910 polyglactin suture (SS)

Study groups in NCT06979687
Study groupRoleWhat they receive
Group 1 (Elective Caesareans undertaken using knotless barbed suture)Elective caesareans undertaken using knotless barbed sutures. This included all cases without exception on the CI's regular operating list from January 2023 (after a positive trial period which resulted in this becoming the standard for the CI). n290.
Receives: Procedure: knotless barbed suture closure of the hysterotomy at caesarean section
Group 2 (Elective caesarean sections on a number of consultant lists using standard sutures SS)May-August 2024 all cases on the respective lists n215
Receives: Procedure: Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)
Group 3 (Emergency caesarean deliveries when KBS was used for closure of the hysterotomy)Emergency caesarean deliveries (category 1-3 urgency - all except elective) using KBS January 2023-December 2024. n 107.
Receives: Procedure: knotless barbed suture closure of the hysterotomy at caesarean section
Group 4 (Emergency caesarean deliveries employing Standard sutures for closure of the hysterotomy)All non-cat 4 CS using SS (May-August 2024) n 345
Receives: Procedure: Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)
Group 5 (comprising all cases in group 1 and group 3)All the KBS caesarean deliveries n 397
Receives: Procedure: knotless barbed suture closure of the hysterotomy at caesarean section
Group 6 (comprising group 2 and group 4)All the SS cases n560
Receives: Procedure: Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-operative infection

    Whether antibiotics were prescribed for a surgical site infective complication.

    Measured: up to 6 weeks post-operative

Secondary outcomes (4)
  1. operating time

    Time from knife to skin to closure of skin

    Measured: Intraoperative

  2. Blood loss

    Estimated or measured intraoperative blood loss (estimates are used unless blood loss is thought excessive when measuring is carried out contemporaneously)

    Measured: In theatre during the operation

  3. Readmission

    Readmission to hospital within 6 weeks post-operative for a maternal indication (not a neonatal one)

    Measured: up to 6 weeks post-operative

  4. Re-attendance as an outpatient

    Attending hospital as an outpatient for an unscheduled review

    Measured: up to 6 weeks post-operative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 May 2025
  2. Study start1 Nov 2022
  3. Primary completion11 Feb 2025
  4. Study completion11 Feb 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
957 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06979687
Sponsor's protocol ID
24/022
Status last verified
Jan 2025
First submitted
13 May 2025
Last updated
29 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: IPD will be shared via CT.gov on an excel spreadsheet without identifiable information being provided

Questions about this trial

What is this clinical trial studying?

An observational study of Caesarean Section and Caesarean Section; Infection, run by South Tees Hospitals NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post-operative infection (time frame: up to 6 weeks post-operative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in